CA2883118A1 - Combinations of sglt 2 inhibitors and antihypertensive drugs - Google Patents

Combinations of sglt 2 inhibitors and antihypertensive drugs Download PDF

Info

Publication number
CA2883118A1
CA2883118A1 CA2883118A CA2883118A CA2883118A1 CA 2883118 A1 CA2883118 A1 CA 2883118A1 CA 2883118 A CA2883118 A CA 2883118A CA 2883118 A CA2883118 A CA 2883118A CA 2883118 A1 CA2883118 A1 CA 2883118A1
Authority
CA
Canada
Prior art keywords
diabetes mellitus
inhibitor
compound
hypertension
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2883118A
Other languages
English (en)
French (fr)
Inventor
Naoki Kojima
J. Richard Roman
Noriyuki Miyata
Teisuke Takahashi
Hideki Tomoike
Takuya TAKEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of CA2883118A1 publication Critical patent/CA2883118A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2883118A 2012-08-30 2013-08-30 Combinations of sglt 2 inhibitors and antihypertensive drugs Abandoned CA2883118A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695016P 2012-08-30 2012-08-30
US61/695016 2012-08-30
PCT/JP2013/073300 WO2014034842A1 (ja) 2012-08-30 2013-08-30 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ

Publications (1)

Publication Number Publication Date
CA2883118A1 true CA2883118A1 (en) 2014-03-06

Family

ID=50183647

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2883118A Abandoned CA2883118A1 (en) 2012-08-30 2013-08-30 Combinations of sglt 2 inhibitors and antihypertensive drugs

Country Status (17)

Country Link
US (1) US9320727B2 (enExample)
EP (1) EP2891499A4 (enExample)
JP (2) JP6198013B2 (enExample)
KR (1) KR20150046125A (enExample)
CN (1) CN104780942A (enExample)
AU (1) AU2013309904A1 (enExample)
BR (1) BR112015004012A2 (enExample)
CA (1) CA2883118A1 (enExample)
HK (1) HK1208621A1 (enExample)
IN (1) IN2015DN01975A (enExample)
MX (1) MX2015002572A (enExample)
PH (1) PH12015500434B1 (enExample)
RU (1) RU2015110979A (enExample)
SG (1) SG11201501510SA (enExample)
TW (1) TW201414472A (enExample)
WO (1) WO2014034842A1 (enExample)
ZA (1) ZA201502009B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (ko) * 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
JP7659783B2 (ja) 2019-09-13 2025-04-10 国立大学法人富山大学 急性心不全における体液貯留改善薬
JP2023523596A (ja) * 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
EP4197543A4 (en) * 2020-08-17 2024-05-15 Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. COMPOSITION AND USE OF SGLT-2 INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS
JP7168133B1 (ja) * 2021-02-19 2022-11-09 大正製薬株式会社 経口フィルム製剤
EP4424309A4 (en) * 2021-10-27 2025-02-26 Meditake Co., Ltd. COMPOSITION WITH ANGIOTENSIN RECEPTOR BLOCKER AND SGLT2 INHIBITOR
CN120417911A (zh) * 2022-12-20 2025-08-01 斯法姆公司 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的用于预防或治疗心血管疾病的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101754972A (zh) * 2007-05-18 2010-06-23 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2010119990A1 (en) * 2009-04-16 2010-10-21 Taisho Pharmaceutical Co., Ltd. Pharmaceutical compositions
JP2012528170A (ja) * 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法

Also Published As

Publication number Publication date
PH12015500434A1 (en) 2015-04-20
MX2015002572A (es) 2015-06-05
RU2015110979A (ru) 2016-10-20
HK1208621A1 (en) 2016-03-11
BR112015004012A2 (pt) 2017-07-04
US9320727B2 (en) 2016-04-26
WO2014034842A1 (ja) 2014-03-06
JP6198013B2 (ja) 2017-09-20
EP2891499A4 (en) 2016-02-24
JPWO2014034842A1 (ja) 2016-08-08
TW201414472A (zh) 2014-04-16
EP2891499A1 (en) 2015-07-08
JP6358515B2 (ja) 2018-07-18
AU2013309904A1 (en) 2015-03-19
ZA201502009B (en) 2016-07-27
JP2017186353A (ja) 2017-10-12
KR20150046125A (ko) 2015-04-29
US20150320721A1 (en) 2015-11-12
CN104780942A (zh) 2015-07-15
PH12015500434B1 (en) 2022-04-22
IN2015DN01975A (enExample) 2015-08-14
SG11201501510SA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
US9320727B2 (en) Combinations of SGLT 2 inhibitors and antihypertensive drugs
EP4321157B1 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
EP2419097B1 (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
CA2829101C (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN107157999A (zh) 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
US9296692B2 (en) Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
CN102256488A (zh) 伴随代谢失衡慢性肾病的治疗组合物和治疗方法
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
WO2020193652A1 (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
EP2948142B1 (en) Combinations with 2-aminoethanesulfonic acid
CN107072977B (zh) Nep抑制剂药物组合及其应用
CN101596195A (zh) 降低血压的口服药物组合物
TW201729801A (zh) 協同性醫藥組合物
KR20150111644A (ko) 미세환경 조절에 의한 근육 손상 예방용 소분자 화합물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180830